The oral drug deucravacitinib (Sotyktu) passed what is probably its final test as a treatment for psoriatic arthritis (PsA), ...

Two studies suggest there is no significant benefit of early biologics over standard step-up care with methotrexate, but ...

The following is a summary of “Clinical and ultrasound features of a cohort of psoriasis patients without musculoskeletal ...

The approval of a new presentation enhances treatment flexibility for children with inflammatory diseases.

Johnson & Johnson (J&J) has reported that Tremfya (guselkumab) minimised the symptoms and signs of active psoriatic arthritis ...

Approval of 45mg/0.5mL solution in a single-dose vial for subcutaneous injection expands dosing flexibility for pediatric patients with plaque psoriasis (PsO) or ...

EULAR - The European Alliance of Associations for Rheumatology - recommends a treat-to-target approach, and suggests more ...

UCB has announced new three-year data from phase 3 trials and their open-label extensions investigating BIMZELX (bimekizumab) ...

European researchers unveil digital tools and explainable AI that personalize psoriatic arthritis care, enabling early ...

Treatment Market is set to acquire a value of USD 11,973.7 million in 2024. By 2034, the value of the psoriatic arthritis (PsA) treatment market is slated to shoot upwards of USD 25,375.6 million. As ...